BRUSSELS, July 1 (Reuters) - Belgian biotech company Innogenetics INNX.BR said on Tuesday it had granted GlaxoSmithKline (GSK.L) a worldwide, non-exclusive license to use its technology in cervical cancer vaccine studies.
Innogenetics said it would receive royalties for each test performed during the studies. GSK agreed to license Innogenetics’ SPF10 primer technology, the Belgian company said in a statement.
U.S. disease diagnosis firm Gen-Probe Inc (GPRO.O) last month launched a 215 million euro ($339.3 million) bid for Innogenetics, trumping an offer from local drugmaker Solvay (SOLB.BR). (Writing by William Schomberg)